Tech Center 1600 • Art Units: 1648 1671
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18274741 | COMPOSITIONS AND METHODS FOR PRODUCING GLYCO-MODIFIED VIRAL ANTIGENS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17261453 | ONCOLYTIC VIRUS CARRYING E-CADHERIN AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 18359154 | SELF-ASSSEMBLING NANOSTRUCTURE VACCINES | Final Rejection | University of Washington |
| 17760174 | POLYPEPTIDES, COMPOSITIONS, AND THEIR USE TO TREAT OR LIMIT DEVELOPMENT OF AN INFECTION | Final Rejection | University of Washington |
| 18030465 | DETECTION OF ACE2 IgM AUTOANTIBODIES AS MARKERS OF SEVERITY AND MECHANISM IN COVID19 PATIENTS | Non-Final OA | The Johns Hopkins University |
| 18040531 | MULTI-EPITOPE VACCINE | Non-Final OA | The Cleveland Clinic Foundation |
| 18029812 | VIRAL VACCINE COMPOSITIONS FOR INOCULATING A SUBJECT AGAINST A CORONAVIRUS, AN INFLUENZA VIRUS, OR BOTH | Non-Final OA | Atossa Therapeutics, Inc. |
| 18500048 | METHODS AND SYSTEMS FOR DETECTION OF MONKEYPOX VIRUS | Non-Final OA | Laboratory Corporation of America Holdings |
| 18275773 | CIS-REPLICON CONSTRUCT | Non-Final OA | ZHENGZHOU UNIVERSITY |
| 18488422 | Recombinant Ranavirus, Methods of Production, and Its Use As A Mammalian Expression System | Non-Final OA | The Trustees of the California State University |
| 17998729 | HIGH-POTENCY SARS CORONAVIRUS 2 ANTIGEN AND VACCINE COMPOSITION COMPRISING SAME | Final Rejection | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY |
| 18286025 | METHODS, KITS, AND APPROACHES FOR VIRAL VACCINES | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18017752 | Antibody/Adjuvant Compositions and Methods of Immune Response Generation against Coronaviruses | Non-Final OA | University of Hawaii |
| 18493133 | LASSA VIRUS VACCINE AND USES THEREOF | Non-Final OA | Inovio Pharmaceuticals, Inc. |
| 18033980 | NUCLEIC ACIDS, PROTEINS, AND VACCINES OF SARS-COV-2 | Non-Final OA | City of Hope |
| 18616452 | MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY | Final Rejection | KYMAB LIMITED |
| 17440639 | SEQUENTIAL HETEROLOGOUS BOOST ONCOLYTIC VIRAL IMMUNOTHERAPY | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 18251620 | DNA ENCODED NANOPARTICLES AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE | Non-Final OA | The Wistar Institute of Anatomy and Biology |
| 18042796 | INTRADERMAL MERS-CoV VACCINE | Final Rejection | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY |
| 18494219 | VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS TO INDUCE IMMUNE RESPONSE | Final Rejection | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. |
| 17771375 | ADOPTIVE IMMUNOTHERAPY | Final Rejection | The Council of the Queensland Institute of Medical Research |
| 18021792 | ENGINEERED ARENAVIRUS GLYCOPROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | The Scripps Research Institute |
| 18556612 | ENGINEERED ARENAVIRUS GLYCOPROTEIN COMPOSITIONS, METHODS AND USE THEREOF | Non-Final OA | LA JOLLA INSTITUTE FOR IMMUNOLOGY |
| 18275925 | ADJUVANTED MUCOSAL SUBUNIT VACCINES FOR PREVENTING SARS-COV-2 TRANSMISSION AND INFECTION | Non-Final OA | The United States of America, as represented by the Secretary, Depart. of Health and Human Services |
| 16631692 | APHERESIS METHODS AND USES | Non-Final OA | SPARK THERAPEUTICS, INC. |
| 18077713 | Human Cytomegalovirus Immunogenic Composition | Non-Final OA | Sanofi Pasteur |
| 18250694 | METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE | Non-Final OA | BIOVAXYS INC. |
| 18249904 | FUSION PROTEIN AND APPLICATION THEREOF | Non-Final OA | BEIJING ABZYMO BIOSCIENCES CO., LTD. |
| 18030633 | VACCINE COMPOSITIONS | Non-Final OA | Virothera Limited |
| 18029766 | COVALENT CONJUGATES OF THE SARS-COV-2 RECEPTOR-BINDING DOMAIN AND A CARRIER PROTEIN AND VACCINE COMPOSITIONS THAT CONTAIN THEM | Non-Final OA | Universidad de la Habana |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy